Pharmacogenomic testing offers enormous potential to manage mental disorders like depression. But many psychoanalysts aren't aware of its value and biotechnical power. This article explains how this form of personalized medicine can be used to aid in the treatment of patients with depression. With over 20 medications approved by the FDA to treat depression, and many others recommended for off-label use, treatment failure with antidepressants commonly occurs in clinical practice. Inviting genetic testing into the treatment plan when working with depressed patients can reduce the rate of medication failure, improve antidepressant compliance and more accurately address resistance in analysis.